Toggle search
Toggle menu
408
21
38
7.1K
Pharmacopedia
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Drilldown: Medicines

More actions

Choose a table:


Medicines > classes : Cathinone or [[:Category:Fibrates|Fibrate]]

Use the filters below to narrow your results.

generic:
3-MMC (1) · Butylone (1) · Cathinone (1) · Ephylone (1) · Ethcathinone (1) · Ethylone (1) · Fenofibrate (1) · Hexedrone (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Pentedrone (1)
brand:
None (14) · Tricor, Lipofen, Antara, Fenoglide, Lofibra, Triglide, Trilipix (fenofibric acid) (1)
classes: (Click arrow to add another value)
mechanism:
Cathinone analogue; monoamine reuptake inhibitor (2) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-000004A9-QINU`"' Modest HDL rise; LDL effects mixed. Renally cleared; combination with statin carries elevated myopathy risk (greater for gemfibrozil than fenofibrate, but caution still warranted)'"`UNIQ--ref-000004AA-QINU`"'. (1)
uses:
None (14) · '"`UNIQ--vote-000004AB-QINU`"', '"`UNIQ--vote-000004AC-QINU`"' (1)
starting dose:
None (14) · Varies by salt form and brand; e.g., Tricor 145 mg PO daily; reduce to 48 mg in renal impairment (1)
preparations:
None (14) · Multiple non-bioequivalent fenofibrate and fenofibric acid formulations: 48-200 mg (1)
fda max:
None (14) · Formulation-specific (e.g., 145 mg/d Tricor, 200 mg/d Lipofen) (1)
routes:
None (14) · Oral (1)
onset:
None (14) · Triglyceride lowering at 4-8 weeks (1)
duration:
None (14) · 24 hours (1)
halflife:
None (14) · ~20 hours (fenofibric acid, the active metabolite)'"`UNIQ--ref-000004AD-QINU`"' (1)
bioavailability:
None (14) · Increased with food (varies by formulation; the micronized and nanocrystal forms are less food-dependent)'"`UNIQ--ref-000004AE-QINU`"' (1)
pregnancy:
None (14) · Limited data; generally avoided unless triglyceride pancreatitis risk is high.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (14) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 15 results in range #1 to #15.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"